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Abstract
Background: Extracorporeal life support (ECLS) is used to support the cardiorespiratory function in case of severe
cardiac and/or respiratory failure in critically ill patients. According to the ELSO guidelines ECLS should be considered
when estimated mortality risk approximates 80%. ECLS seems an efficient therapy in terms of survival benefit, but no
undisputed evidence is delivered yet. The aim of the study is to assess the health-related quality of life after ECLS
treatment and its cost effectiveness.
Methods: We will perform a prospective observational cohort study. All adult patients who receive ECLS in
the participating centers will be included. Exclusion criteria are patients in whom the ECLS is only used to
bridge a procedure (like a high risk percutaneous coronary intervention or surgery) or the absence of informed consent.
Data collection includes patient characteristics and data specific for ECLS treatment. Severity of illness and mortality risk is
measured as precisely as possible using measurements for the appropriate age group and organ failure. For analyses on
survival patients will act as their own control as we compare the actual survival with the estimated mortality on initiation
of ECLS if conservative treatment would have been continued. Survivors are asked to complete validated questionnaires
on health related quality of life (EQ5D-5 L) and on medical consumption and productivity losses (iMTA/iPCQ) at 6 and
12 months. Also the health related quality of life 1 month prior to ECLS initiation will be obtained by a questionnaire, if
needed provided by relatives. With an estimated overall survival of 62% 210 patients need to be recruited to make a
statement on cost effectiveness for all ECLS indications.
Discussion: If our hypothesis that ECLS treatment is cost-effective is confirmed by this prospective study this could lead
to an even broader use of ECLS treatment.
Trial registration: The trial is registered at (NCT02837419) registration date July 19, 2016 and with the Dutch trial
register, http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=6599
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Background
Extracorporeal life support (ECLS) by means of extracor-
poreal membrane oxygenation (ECMO) utilization can sup-
port the heart and lung for an extended period of time, up
to months, an is deployed in the Intensive Care Unit (ICU).
The indication for ECLS is acute, potentially reversible car-
diac or respiratory failure, when conventional therapy has
been inadequate [1]. In addition, ECLS can also be used in
patients with terminal respiratory or cardiac failure as a
bridge to transplant, and to support cardiopulmonary
resuscitation; extracorporeal cardiopulmonary resuscitation.
ECMO is proven beneficial in mature infants with
severe but potentially reversible respiratory failure leading
to a significantly improved survival without increased risk
of severe disability [2]. The increased use of ECLS after
the CESAR trial, during the H1N1 pandemic and advances
in device technology renewed interest in ECLS utilization
in adults [3]. ECLS seems an efficient therapy for cardiac
and respiratory failure, but unfortunately no undisputed
evidence from randomized controlled trials is delivered
yet. Furthermore, currently no detailed information on
costs of ECLS therapy is available. The urge for economic
evaluations emerges from the increasing deployment of
ECLS. The CESAR trial was the first adult trial performed
for cost comparison between ECLS and mechanical venti-
lation for severe adult respiratory distress syndrome
(ARDS) [3]. This trial provided data concerning the sub-
group of patients with severe ARDS suitable for veno-
venous ECLS and compared referral to a center that of-
fered ECLS with conventional management at the original
center, not ECLS therapy itself; 68 out of 90 referred
patients actually received ECLS therapy. Mean health-care
costs per patient were more than twice as high for patients
allocated to consideration for ECLS than for those allo-
cated to conventional management. We previously per-
formed a detailed exploratory cost study to gain insight in
the hospital costs related to ECLS therapy regardless of in-
dication and found that an ECLS patient carried a mean
total hospital cost of €109.407. With a total of 72 patients,
our study is the largest economic evaluation, providing a
detailed insight of hospital costs in adults treated with
ECLS and thus constitutes a first step in assessing it’s
cost-effectiveness [4]. The next step in assessing the cost-
effectiveness of ECLS therapy is to proceed with an eco-
nomic evaluation in which costs from a societal perspec-
tive are considered. More knowledge about outcome
variables such as life years gained and quality adjusted life
years (QALY’s) needs to be gathered in a prospective man-
ner. Then, interpretation of the total hospital costs in con-
text to the outcome of ECLS patients is possible with the
aim to study whether patients actually benefit from ECLS
treatment and at what costs.
A direct comparison between usual care and ECLS, e.g.
by means of a randomized trial, is very complex since
standard treatment (no ECLS) will result in death in a vast
majority of cases. However, several ICU scoring systems
exist that predict hospital mortality of individual patients.
Depending on the indication, i.e. underlying disease, RESP
score, SAVE-score, APACHE-4, SAPS-III or SOFA score
are the most reliable for that purpose [5–9].
Methods/design
The design is a multi-center prospective observational
cohort study with the aim to assess the health-related qual-
ity of life after ECLS treatment and the associated costs.
We expect that survivors of ECLS therapy have a good
quality of life and life expectancy. Lifetime predicted costs
for QALYs are expected to be cost-effective. Therefore our
hypothesis is that ECLS treatment is cost effective.
Inclusion criteria
All adult patients who receive ECLS will be included.
With our consortium we cover nearly all ECLS treat-
ments in The Netherlands. In general, according to
the ELSO guidelines, ECLS can be considered in
acute severe heart and/or lung failure with high mor-
tality risk despite optimal conventional therapy. ECLS
is indicated in most circumstances at 80% mortality
risk. Severity of illness and mortality risk is measured
as precisely as possible using measurements for the
appropriate age group and organ failure.
Exclusion criteria
Patients in whom the ECLS in only used to bridge a pro-
cedure like a high risk percutaneous coronary intervention
or during surgery.
Ethics
The need for ethical approval was waived by the
institutional medical ethics board of the University
Medical Center of Groningen (protocol number METc
2017/196), and written informed consent will be obtained
from all patients or legal representatives.
The predicted mortality for every patient at the
initiation of ECLS is used and compared with the
actual mortality at one year of each patient. That
means that every patient acts as his own control.
Depending on the indication or the underlying dis-
ease, the APACHE-4, SOFA score, RESP score, or
SAVE score will be used to estimate mortality. Al-
though the used models predict hospital mortality in-
stead of one year mortality, the vast majority of
mortality is during hospital admission, so the used
mortality prediction is expected to be valid for one
year survival analyses as well [10, 11].
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Outcome measures
The primary outcome is health related quality of life
assessed with the EQ-5D-5 L questioning list 12 months
after initiation of ECS treatment.
The EQ-5D-5 L questioning list consists of a descrip-
tive system with 5 domains (mobility, self-care, usual
activities, pain/discomfort, anxiety/depression) with 5
possible levels on each which can be converted in to a
single summary index score, which represents the soci-
etal perspective on quality of life (QoL), and a score on a
visual analogue scale, which represents the patient’s per-
spective in QoL. The iMTA questionnaire is used to
assess medical consumption at 6 and 12 months after
initiation of ECLS treatment. The iPCQ questionnaire is
used to assess productivity losses at 6 and 12 months
after initiation of ECLS treatment.
Secondary outcome is one year survival. Additional
measurements are EQ-5D-visual analog scale (VAS)
score and societal costs. Same parameters are assessed at
6 months, and 1 month before ECLS treatment, the lat-
ter retrospectively provided at admission, if needed by
relatives.
Subgroup analysis
In order to estimate cost-efficacy of ECLS based on indica-
tion patients will be categorized into six different sub-
groups: respiratory – bridge to recovery, respiratory –
bridge to transplant, cardiac – bridge to recovery, cardiac –
bridge to transplant, cardiac – post-cardiotomy, and extra-
corporeal cardiopulmonary resuscitation.
Sample size calculation
Sample size calculation is based on survival with a good
health related-QoL assessed with the EQ-5D-VAS ques-
tionnaire one year after initiation of ECLS treatment.
Predicted mortality in usual care is 80%. Overall,
expected mortality in patients with ECLS treatment is
38%. The increase in survival is thus 42%. To demon-
strate an effect on survival 25 patients are needed: risk
ratio 0.48 (95%CI 0.28–0.82). In usual care 90% will have
a poor outcome, for sake of power analysis defined as
dead or an EQ-5D-VAS below the median. With ECLS
treatment this will be 69% so 132 patients are needed to
demonstrate an effect on QoL. To compensate for a 5%
less effect and 5% drop-outs 210 patients will be enrolled
to include 200 patients with complete follow-up in the
final analysis (RR 0.82; 95%CI 0.75–0.90). Based on a
38% mortality and a study duration of 3 years, 124 (62%
out of 200) patients have a complete one year follow-up
at the end of the study.
Statistics
With the additional information on costs (apart from
direct hospital costs already available) assessed within
this study it is now possible to calculate the costs of
ECLS therapy related to mortality. Based on case-fatality
and health related-QoL we will be able to assess QALY’s.
For this calculation the predicted mortality at initiation
of ECLS therapy is used for comparison. Many patients
treated with ECLS survive only after lung transplant-
ation, heart transplantation or implantation of a left ven-
tricular assist device. Life expectancy of the study
population can thus be based on the average expecta-
tions of that particular patient category. The remaining
patients who were treated with ECLS as a bridge to re-
covery have a reasonable good quality of life [10, 12].
Based on our follow-up study of ICU patients we expect
that the median health related-QoL in surviving patients
will be 0.83 after one year, which results in 0.36 QALY
gained per treated patient. Although additional total
healthcare costs and loss of income will be substantial
and assumed to exceed €172,200 after one year com-
pared with usual care, lifetime-predicted costs and
QALYs is expected to be cost-effective due to the rela-
tively good life-expectancy of survivors. With data from
200 patients of which 62% survive until one-year follow-
up we will be able to make a statement about cost-
effectiveness for all indications for ECLS.
A cost effectiveness analysis as well as a Budget Impact
Analysis will be performed in accordance with the Dutch
guidelines [13, 14].
Cost effectiveness analysis (CEA)
In the economic evaluation, the primary aim will be
to estimate societal costs of ECLS utilization. The
secondary aim will be to estimate the cost effective-
ness and cost utility of ECLS utilization compared to
usual care (from a societal perspective). The cost
effectiveness analysis will be performed based on sur-
vival. The costs utility analysis will be performed
based on EuroQol (EQ-5D-5 L) defined utilities. Re-
sults of the cost utility analysis will display the extra
costs or savings of ECLS, in order to gain one QALY,
compared to usual care. The time horizon of this
clinical study will be 1 year, therefore the analysis will
not include discounting of costs and effects. Scenario
analyses are planned within the trial based evaluation
as well as in the model that estimated the effects over
a life time horizon. Bootstrap re-sampling will be per-
formed on the cost and effect pairs in order to calcu-
late confidence intervals. Furthermore, cost effectiveness
acceptability curves will be plotted, to estimate the prob-
ability that ECLS is more cost-effective than usual care,
for different amounts of money that a decision maker may
be willing to pay for one additional QALY. The trial based
results of the CEA, together with available data from lit-
erature, will be extrapolated to a life time horizon, using
decision modeling in a secondary analysis.
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Cost analysis
All direct medical cost items, expected to be affected by the
ECLS therapy will be registered on a patient level, and
valued according to the Dutch standard guidelines for eco-
nomic evaluations [14]. Non-medical costs such as trans-
portation to an ECLS center, informal care and productivity
losses/regained productivity (of patient and partner) will be
measured by means of a question in the questionnaire.
Costs of resource use outside the hospital, such as product-
ivity losses or traveling expenses will be collected using the
relevant parts of the iMTA cost questionnaires.
Patient outcome analysis
Utility will be measured using the EuroQol (EQ-5D-5 L)
at six months and one year. In order to value the EQ-5D
profiles, the new Dutch algorithm will be used [15]. The
use of the EQ-5D as a generic measure in economic evalu-
ations facilitates the comparability of (cost effectiveness)
results across different studies and interventions.
Budget impact analysis (BIA)
Budget impact analysis will be performed from a health
care perspective, and in addition from health insurance
perspective. The base care scenario will focus on 1 year
impact on a national level. Scenario analysis will adopt a
5 to 10 year horizon (life time).
Cost-analysis: A BIA will be conducted to inform
decision-makers about the financial consequences of the
adoption and diffusion of the use of ECLS in the Dutch
healthcare system. The BIA will use a deterministic
model. The model input parameters will mainly be based
on results of the recently conducted cost study (hospital
perspective), the current clinical and cost-effectiveness
study, and available literature. The analyses will be con-
ducted from various perspectives, including a direct
medical perspective, a budgetary care perspective and a
health insurers perspective. For the analysis from a dir-
ect medical perspective, only cost within the healthcare
sector will be taken into account. Unit prices will be
based on Dutch standard prices. For the other perspec-
tives, national tariffs will be applied and the scope of in-
cluded costs will be limited to those relevant for the
perspective concerned. The precision of costs will be in
accordance with the described perspectives (€M).
Given the fact that for the populations under study,
the standard care consists of ‘no ECLS’, the model will
only take changes in the availability and adoption of the
use of ECLS into account by calculating the financial
consequences of the following scenarios:
– Situation in which all patients that are in principal
suitable to use receive ECLS treatment, will receive
standard care in the hospital, according to the
current practice, which means no ECLS
– Situation in which all suitable patients receive ECLS
according to the current study protocol
– Situation in which ECLS utilization will gradually be
implemented in new hospitals.
– Situation in which ECLS is considered suitable and
available for varying percentages of the targeted
population
– Situation in which the indication for ECLS will
gradually be broadened.
For each of the presented scenarios, a time horizon up
to 5–10 years will be applied. Alternative time horizons
will be addressed in sensitivity analyses. Costs will be
calculated based on changes in resource use, valued
against the price level relevant from the various perspec-
tives. Discounting of future costs will not be applied in
the BIA. The model will allow additional analyses for
subgroups of patients. These analyses mainly include the
shift in the subgroups of patients based on indication
and severity. Budget information for relevant subgroups
will be made available for decision makers. The planned
sensitivity analysis will address the main input parame-
ters and assumptions of the model, and financial conse-
quences of variations in model parameters will be
calculated for each of the applied perspectives [16].
Discussion
The study uses a prospective observational design and
not of a randomized controlled trial. A randomized con-
trolled trial in ECLS would be very challenging for both
the logistic and ethical reasons. We expect in the current
time that the initiation of a randomized controlled trial
would lead to bias and therefore impairing the external
validity of the results. Our observational design with the
use of predicted mortality of individual patients at the
moment of initiating of ECLS as an internal comparison
resembles the methods of a randomized controlled trial
the most. In contrast to a randomized controlled trial
our design prevents bias on the basis of indication and
selection because all consecutive patients will be
included. This guarantees the inclusion of a real world
patient population that is clinical relevant.
ECLS is currently offered in many centers worldwide,
but application per population range enormously even
within countries. It is estimated that in some regions the
amount of eligible patients is 10-fold the current num-
ber. Although assumed to be beneficial in terms of life
saving application may be hampered by the apparent
high costs and that ECLS is not covered by the health
insurance in some countries. In summary, we expect
that ECLS treatment is cost-effectiveness, in this case
defined as having an additional benefit worth the add-
itional cost. When cost-effectiveness is made plausible, a
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gradual increase in ECLS therapy is expected from
which many patients will benefit.
Trial status
The trial is registered at https://clinicaltrials.gov/
(NCT02837419), registration date July 19, 2016.
The trial is registered at the Dutch Trial Register at July 27
2017 http://www.trialregister.nl/trialreg/admin/rctview.asp?
TC=6599
Recruitment will start at December 2017, recruiting dur-
ing 18–24 months, with a 1 year follow up.
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